Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biomaterials ; 26(11): 1299-306, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15475060

ABSTRACT

We report a preliminary study concerning the encapsulation modalities in nanoparticles of the anti-ischemic drug N6-cyclopentyladenosine (CPA) and its pro-drug 5'-octanoyl-CPA (Oct-CPA). The release of these compounds and the related pro-drug stability effects in human whole blood have been tested. Moreover, the influence of the delivery systems on CPA interaction toward human adenosine A1 receptor has been analysed. The nanospheres were prepared by nanoprecipitation or double emulsion solvent evaporation method using poly(lactic acid) and recovered by gel filtration or ultracentrifugation or dialysis. Free and encapsulated Oct-CPA was incubated in fresh blood and its stability was analysed with HPLC. Quite spherical nanoparticles with mean diameters ranging between 210+/-50 and 390+/-90 nm were obtained. No encapsulation occurred when CPA was used. Satisfactory results concerning drug content (0.1-1.1% w/w) and encapsulation efficiency (6-56%) were achieved when Oct-CPA was employed. The controlled release of the pro-drug was achieved, being released within a range of 1-4 h, or very slowly, depending on nanoparticle preparations. The hydrolysis rate of Oct-CPA in human whole blood appeared stabilized in human whole blood with modalities related to the release patterns. The presence of all nanoparticle preparations did not interfere with CPA interaction at its action site.


Subject(s)
Adenosine/administration & dosage , Adenosine/pharmacokinetics , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/pharmacokinetics , Drug Carriers/chemistry , Nanotubes/chemistry , Receptor, Adenosine A1/metabolism , Absorbable Implants , Adenosine/analogs & derivatives , Adenosine/blood , Animals , CHO Cells , Cricetinae , Cricetulus , Delayed-Action Preparations/chemistry , Diffusion , Humans , Lactic Acid/chemistry , Metabolic Clearance Rate , Nanotubes/ultrastructure , Particle Size , Polyesters , Polymers/chemistry , Vasodilator Agents/administration & dosage , Vasodilator Agents/blood , Vasodilator Agents/pharmacokinetics
2.
Int J Pharm ; 278(1): 133-41, 2004 Jun 18.
Article in English | MEDLINE | ID: mdl-15158956

ABSTRACT

Cloricromene (AD6), an anti-ischemic drug, is rapidly metabolised into a stable and active metabolite (cloricromene acid, AD6-acid) poorly soluble in water and less lipophilic than cloricromene. The aim of this study was to evaluate which of the two forms has more possibility to be efficiently encapsulated in nanoparticles based on poly(D,L-lactide) and prepared using the nanoprecipitation method. Increasing the theoretical loading of AD6, an increase in drug actual loading and in the mean particle size occurred, while no formation of nanoparticles was observed when the highest theoretical loading (50 mg) was employed. Changing the pH of the aqueous phase the drug content dramatically increased. However, at a pH value of 11 a more rapid hydrolysis of AD6 occurred. When AD6-acid was embedded in the nanoparticles, suitable results concerning both drug content and encapsulation efficiency were achieved. A good control in the release of AD6 from the AD6-loaded nanoparticles was observed while the liberation of AD6-acid from the AD6-acid-loaded nanoparticles was faster than the dissolution of the AD6-acid free. These results confirm that the most easy encapsulable form in nanoparticles is AD6-acid probably owing to its poor water solubility. Further studies will be carried out in order to evaluate if the increase in the liberation of AD6-acid by nanoencapsulation may have outcomes in its bioavaibility in vivo.


Subject(s)
Chromonar/analogs & derivatives , Lipids/chemistry , Nanotechnology/methods , Polyesters/chemistry , Water/chemistry , Chromonar/chemistry , Chromonar/pharmacokinetics , Drug Evaluation, Preclinical/methods , Hydrogen-Ion Concentration , Lipids/pharmacokinetics , Microscopy, Electron, Scanning , Polyesters/pharmacokinetics , Solubility/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...